Sperogenix Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Latest Deal Type
-
Series B
- Investors
-
4
Sperogenix Therapeutics General Information
Description
Operator of a platform and developer of treatments for rare and underserved medical conditions intended for therapeutic use. The company provides clinical development, customer communication, and business expansion services to medical businesses at the late clinical stage and commercialization stage, enabling clients to bring benefits to millions of people with rare diseases in China.
Contact Information
Website
www.sperogenix.comCorporate Office
- Building A, Innovation Park
- Number 56 Dongzhimenwai Xiejie, Chaoyang District
- Beijing, 100027
- China
Corporate Office
- Building A, Innovation Park
- Number 56 Dongzhimenwai Xiejie, Chaoyang District
- Beijing, 100027
- China
Sperogenix Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 23-Oct-2023 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A1) | 31-Dec-2021 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 10-May-2019 | Completed | Generating Revenue |
Sperogenix Therapeutics Patents
Sperogenix Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4532492-A1 | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof | Pending | 25-May-2022 | ||
| EP-4532492-A4 | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof | Pending | 25-May-2022 | ||
| US-20250346587-A1 | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof | Pending | 25-May-2022 | ||
| WO-2023226658-A1 | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof | Inactive | 25-May-2022 | ||
| EP-4298095-A1 | Heterocyclic compounds as kinase inhibitor and uses thereof | Pending | 30-Jan-2021 | C07D403/12 |
Sperogenix Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jiangsu Dingxin Capital Management | Venture Capital | Minority | ||
| Prosperico Ventures | Venture Capital | Minority | ||
| 5Y Capital | Venture Capital | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority |
Sperogenix Therapeutics FAQs
-
When was Sperogenix Therapeutics founded?
Sperogenix Therapeutics was founded in 2015.
-
Where is Sperogenix Therapeutics headquartered?
Sperogenix Therapeutics is headquartered in Beijing, China.
-
What industry is Sperogenix Therapeutics in?
Sperogenix Therapeutics’s primary industry is Enterprise Systems (Healthcare).
-
Is Sperogenix Therapeutics a private or public company?
Sperogenix Therapeutics is a Private company.
-
What is Sperogenix Therapeutics’s current revenue?
The current revenue for Sperogenix Therapeutics is .
-
How much funding has Sperogenix Therapeutics raised over time?
Sperogenix Therapeutics has raised $30M.
-
Who are Sperogenix Therapeutics’s investors?
Jiangsu Dingxin Capital Management, Prosperico Ventures, 5Y Capital, and LAV (Lilly Asia Fund) have invested in Sperogenix Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process